Each step. Every patient. Exactly what you need.
Schedule a meeting with us
We’re excited to connect with you while in San Francisco! Visit our booth space #20 to learn how the Prolaris® Prostate Cancer Prognostic Test outperforms all other biomarkers—and is the leading test for confident active surveillance (AS) decision-making.1,2
ASCO GU Symposium
Location: Moscone Center, San Francisco, CA
When: 2/26 – 2/28
Booth: #20
We're proud to share that 6 abstracts have been accepted
The Prolaris test on diagnostic biopsy for localized prostate cancer prognosis across risk groups and management: An individual participant data meta-analysis.
Presenter: Steven Monda, MD, University of Michigan
Date: Thursday, February 26, 2026
Time: 11:30 AM - 12:45 PM PST | 5:45 PM - 6:45 PM PST
Rethinking germline testing in localized prostate cancer: Prevalence of germline variants and association with Gleason score and NCCN risk grouping.
Presenter: Adam Cole, MD, TruCore Pathology
Ultra-sensitive molecular residual disease detection via tumor-informed whole-genome sequencing-based ctDNA assay in resectable urothelial cancer in the MONSTAR-SCREEN-3 project
Presenter: Shigehiro Tsukahara, Kyushu University | Fukuoka, Japan
Date: Friday, February 27, 2026
Time: 11:30 AM - 12:45 PM PST | 4:45 PM - 5:45 PM PST
CONSOLIDATE: Interim Results from a Phase I/II study of radiotherapy combined with enfortumab vedotin (EV) for locally advanced bladder cancer with paired translational ctDNA and utDNA
Presenter: Patrick Carriere, MD, MD Anderson Cancer Center
Circulating KIM-1 and ctDNA as prognostic markers in oligometastatic clear cell renal cell carcinoma (ccRCC): The K-COMPASS model.
Presenter: Chad Tang, MD, MD Anderson Cancer Center
Date: Saturday, February 28, 2026
Time: 12:45 PM - 1:30 PM PST
Ultra-sensitive whole-genome sequencing-based molecular residual disease detection in resectable renal cell carcinoma: Preliminary results from the MONSTAR-SCREEN-3 study
Presenter: Taigo Kato, MD, PhD, Osaka University | Osaka, Japan
Request more information about how Myriad’s Oncology solutions can benefit you/your patients.
By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.
Contact Information
©Myriad Genetics, Myriad Oncology, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific.